These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16356302)

  • 21. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
    Wasserman E; Sutherland W; Cvitkovic E
    Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
    Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M
    J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
    Sasaki Y; Hamaguchi T; Arai T; Goto A; Ura T; Muro K; Yamada Y; Shirao K; Shimada Y
    Anticancer Res; 2014 Apr; 34(4):2029-34. PubMed ID: 24692743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
    Saunders MP; Hogg M; Carrington B; Sjursen AM; Allen J; Beech J; Swindell R; Valle JW
    Br J Cancer; 2004 Oct; 91(8):1447-52. PubMed ID: 15452550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
    Hartmann JT; Pintoffl JP; Kröning H; Bokemeyer C; Holtmann M; Höhler T
    Onkologie; 2008 May; 31(5):237-41. PubMed ID: 18497512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
    Wasserman E; Cuvier C; Lokiec F; Goldwasser F; Kalla S; Méry-Mignard D; Ouldkaci M; Besmaine A; Dupont-André G; Mahjoubi M; Marty M; Misset JL; Cvitkovic E
    J Clin Oncol; 1999 Jun; 17(6):1751-9. PubMed ID: 10561212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
    Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
    Tai CJ; Liu JH; Chen WS; Lin JK; Wang WS; Yen CC; Chiou TJ; Chen PM
    Jpn J Clin Oncol; 2003 Mar; 33(3):136-40. PubMed ID: 12672791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
    Lee MA; Byun JH; Shim BY; Woo IS; Kang JH; Hong YS; Lee KS; Choi MG; Chang SK; Oh ST; Choi SI; Lee DS
    Korean J Intern Med; 2005 Sep; 20(3):205-9. PubMed ID: 16295778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
    Kouroussis C; Souglakos J; Mavroudis D; Papadouris S; Kakolyris S; Agelaki S; Kalbakis K; Panopoulos C; Vardakis N; Sarra E; Georgoulias V
    Am J Clin Oncol; 2002 Dec; 25(6):627-31. PubMed ID: 12478014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
    Song Y; Li WW; Huang J
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
    [No Abstract]   [Full Text] [Related]  

  • 36. Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
    Calvo E; Cortés J; González-Cao M; Rodríguez J; Aramendía JM; Fernández-Hidalgo O; Martín-Algarra S; Salgado JE; Martínez-Monge R; de Irala J; Brugarolas A
    Oncology; 2002; 63(3):254-65. PubMed ID: 12381905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
    Hartmann JT; Oechsle K; Jäger E; Reis HE; Haag C; Niederle N; Wilke HJ; Pflüger KH; Batran SA; Büchele T; Hofheinz RD; Kanz L; Bokemeyer C
    Anticancer Drugs; 2004 Jun; 15(5):473-7. PubMed ID: 15166621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.